According to a 2019 survey, 71 percent of adults in the U.S. are knowledgeable about the meaning of the term "antibiotic resistance", whereas 15 percent of those surveyed indicated that they have never heard of this term. This statistic shows public familiarity with the terms antibiotic resistance, superbugs, and anti-vaxxers in the U.S. in 2019.

Number of deaths registered in Northern Ireland where Clostridium Difficile was mentioned on the death certificate.

Source agency: Northern Ireland Statistics and Research Agency

Designation: National Statistics

Language: English

Alternative title: Deaths Registered with Clostridium Difficile (Northern Ireland)

Number of deaths registered in Northern Ireland where MRSA was mentioned on the death certificate.

Source agency: Northern Ireland Statistics and Research Agency

Designation: National Statistics

Language: English

Alternative title: Deaths Registered with MRSA mentioned on the death certificate (Northern Ireland)

The world is facing a crisis in treating infectious diseases, with a scarcity of new antibiotics in development to treat the growing threat of drug-resistant “superbugs”. We need new strategies to reinvigorate the antibiotic pipeline. In this Viewpoint we discuss one such approach, encouraging the community of synthetic chemists to participate in testing chemical diversity from their laboratories for antimicrobial potential. CO-ADD, the Community for Open Antimicrobial Drug Discovery, offers free screening against five bacteria and two fungi with follow up hit confirmation and validation, all with no strings attached.

Polymyxins are increasingly the last option available to treat patients with infections caused by antibiotic-resistant bacteria known as Gram-negative ‘superbugs'. Polymyxins were developed more than 50 years ago, before the advent of modern drug development and approval procedures. Due to a lack of clinical data, there were difficulties administering the drugs with the right dose and at the right time, with patients falling ill due to potential toxicity. The recent emergence of 'superbugs' resistant to all other antibiotics has led to a renewed interest in polymyxins. The study has involved testing (using techniques such as chromography) of samples from animals and from more than 200 patients in the US, Thailand, Brazil and Greece. Raw data from these experiments (500Gb, and around 100,000 data files in total) are used to support statistical analysis and modelling. This dataset is an output of an ongoing research program that includes a collaboration between Monash University (Prof Roger Nation, Assoc Prof Jian Li, Dr Tony Velkov, Dr Ian Larson, Prof Ben Adler, Dr John Boyce, Prof Paul Hertzog, Dr Jinhua Li), the Austin Hospital (Dr Ben Howden), the Alfred Hospital (Assoc Prof Dennis Spelman), the Women's and Children Hospital (Prof John Turnidge), St Vincent's Hospital (Assoc Prof Prue Hill), University of Pittsburgh (Dr Fernanda Silveira), University of Queensland (Prof David Paterson, Prof Matt Cooper), Mahidol University in Thailand (Prof Visanu Thamlikitkul) and the State University of New York at Buffalo (Prof Alan Forrest, Dr Brian Tsuji). More than 63 journal articles have resulted from this program of research.

The antimicrobial resistant organisms (AMRO), also known as superbugs, are invisible and can survive up to three days on certain surfaces. This means they can be transferred whenever an infected person simply touches another, or by contact with an object on which the bugs are thriving, such as a stethoscope or a TV remote. Infections caused by these microorganisms often fail to respond to standard treatment, resulting in prolonged hospital stays, higher healthcare costs, and an increased risk of death. To address this problem in an innovative way, the ANTI-SUPERBUGS PCP project, led by Dr. Enrique Limón, researcher at Bellvitge Biomedical Research Institute (IDIBELL) was launched last September 1st. The project, which will last for four years, is part of the pre-commercial procurement (PCP) initiatives funded by the European Commission’s H2020 framework program. "Resistance to antibiotics varies depending on geographic location and is directly proportional to the use and misuse of antibiotics," explains Dr. Enrique Limón. "There are active surveillance systems, implemented in all European states, thanks to which infections by resistant microorganisms have decreased in recent years, but unfortunately the efforts made so far are not enough to eradicate them." The microbiology services play a fundamental role in the identification and monitoring of "superbugs", but time of diagnosis remains as an unresolved issue that affects all prevention and treatment strategies carried out by the infectious diseases services; that is the main reason behind ANTI-SUPERBUGS PCP. "We want to challenge the industry to develop innovative, smart ICT solutions that detect the presence of resistance microorganisms, give real-time feedback to the user and share the information with the healthcare provider's electronic record systems linking the infection with the place of detection" says Dr. Limón. Pre-commercial procurement (PCP) is the acquisition of research and development of new innovative solutions before they become available on the market. The support of European Commission to the CPP projects is expanding in its latest Horizon 2020 framework program, with financial incentives such as the PCP Co-Fund actions available for consortia of public procurers working together on joint PCPs within the domain of research and innovation defined under each different program.

Candida auris has emerged as a serious threat of public health and caused global epidemic due to multi-drug resistance, remarkable transmissibility and high mortality. To tackle the challenging super fungus, novel benzoanilide antifungal agents were discovered by an integrated strategy of phenotypic screen, hit optimization, antifungal assays and mechanism exploration. The most promising compound A1 showed potent in vitro and in vivo efficacy against Candida auris infection. Mechanism investigation revealed that compound A1 blocked the biosynthesis of virulence factors and fungal cell walls through the inhibition of glycosylphosphatidylinositol (GPI) and GPI-anchored proteins. Thus, compound A1 represents a promising lead compound to combat drug-resistant candidiasis.

Graphene oxide (GO) is a derivative of graphene nanosheet which is the most promising material of the decade in biomedical research. In particular, it has been known as an antimicrobial nanomaterial with good biocompatibility. In this study, we have synthesized and characterize GO and checked its antimicrobial property against different Gram-negative and Gram-positive multi drug resistant (MDR) hospital superbugs grown in solid agar-based nutrient plates with and without human serum through the utilization of agar well diffusion method, live/dead fluorescent staining and genotoxicity analysis. The main focus of the antimicrobial activity analysis is to distinguish the killing performance of GO in artificial and blood containing media because after injection into the bloodstream the activity of GO may be modified by adsorption of blood proteins or other biomolecules. No significant changes in antibacterial activity were found in these two different conditions. We also compare the bactericidal capability of GO with some commonly administrated antibiotics and in all cases the degree of inhibition is found to be higher. The data presented here are novel and show that GO is an effective bactericidal agents against different superbugs and can be used as a future antibacterial agent.

This analysis presents a rigorous exploration of financial data, incorporating a diverse range of statistical features. By providing a robust foundation, it facilitates advanced research and innovative modeling techniques within the field of finance.

Pfizer's New Antibiotic Could Be a Game-Changer in the Fight Against Superbugs

Financial data:

• Historical daily stock prices (open, high, low, close, volume)

• Fundamental data (e.g., market capitalization, price to earnings P/E ratio, dividend yield, earnings per share EPS, price to earnings growth, debt-to-equity ratio, price-to-book ratio, current ratio, free cash flow, projected earnings growth, return on equity, dividend payout ratio, price to sales ratio, credit rating)

• Technical indicators (e.g., moving averages, RSI, MACD, average directional index, aroon oscillator, stochastic oscillator, on-balance volume, accumulation/distribution A/D line, parabolic SAR indicator, bollinger bands indicators, fibonacci, williams percent range, commodity channel index)

Machine learning features:

• Feature engineering based on financial data and technical indicators

• Sentiment analysis data from social media and news articles

• Macroeconomic data (e.g., GDP, unemployment rate, interest rates, consumer spending, building permits, consumer confidence, inflation, producer price index, money supply, home sales, retail sales, bond yields)

Potential Applications:

• Stock price prediction

• Portfolio optimization

• Algorithmic trading

• Market sentiment analysis

• Risk management

Use Cases:

• Researchers investigating the effectiveness of machine learning in stock market prediction

• Analysts developing quantitative trading Buy/Sell strategies

• Individuals interested in building their own stock market prediction models

• Students learning about machine learning and financial applications

Additional Notes:

• The dataset may include different levels of granularity (e.g., daily, hourly)

• Data cleaning and preprocessing are essential before model training

• Regular updates are recommended to maintain the accuracy and relevance of the data

BackgroundCarbapenem-resistant Gram-negative bacteria (CR-GNB) pose a serious global health threat, especially in low- and middle-income countries. Local surveillance is crucial for informing antimicrobial stewardship and infection control strategies. This study aimed to evaluate the prevalence, demographic distribution, and temporal fluctuations of carbapenem resistance among key Gram-negative pathogens in a South Indian tertiary care center over a two-year period.MethodsA retrospective study was conducted on 8,359 non-duplicate Gram-negative isolates obtained from clinical specimens between July 2022 and July 2024. Organisms were identified, and antimicrobial susceptibility was determined using the VITEK® 2 Compact system (BioMérieux). Resistance to imipenem (IPM) and meropenem (MEM) was assessed. Data were stratified by age, sex, ward type, specimen source, and quarterly distribution. A subset of resistant isolates underwent molecular screening for carbapenemase genes using real time PCR.ResultsCarbapenem resistance was observed in 24% (2007) of Gram-negative isolates. Acinetobacter baumannii (48.0%) and Klebsiella pneumoniae (38.6%) accounted for the majority of resistant cases. Resistance was significantly higher in males (64.3%) and in patients aged 61–80 years (p

Snapshot img

The urinary tract infection (UTI) treatment market share is expected to increase by USD 2.66 million from 2020 to 2025, and the market’s growth momentum will accelerate at a CAGR of 4.71%.

This urinary tract infection (UTI) treatment market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers urinary tract infection (UTI) treatment market segmentation by type (uncomplicated UTI and complicated UTI) and geography (North America, Europe, Asia, and ROW). The urinary tract infection (UTI) treatment market report also offers information on several market vendors, including Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Pfizer Inc., and SHIONOGI Co. Ltd. among others.

What will the Urinary Tract Infection (UTI) Treatment Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Urinary Tract Infection (UTI) Treatment Market Size for the Forecast Period and Other Important Statistics

Urinary Tract Infection (UTI) Treatment Market: Key Drivers, Trends, and Challenges

The relation of UTI with several other factors leading to a rising incidence rate of UTI is notably driving the urinary tract infection (UTI) treatment market growth, although factors such as the development of antibacterial resistance may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the urinary tract infection (UTI) treatment industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Urinary Tract Infection (UTI) Treatment Market Driver

One of the key factors driving growth in the urinary tract infection treatment market is the rising incidence rate of UTIs. Interconnection of UTIs with other healthcare conditions and changing lifestyle habits have led to the rising incidence of the disease. This, in turn, is expected to raise the demand for treatment facilities for UTIs. The disease is more common in women as compared with men. Around 50% of the women globally have a chance of developing UTIs at least once in their lifetime. This accounts for a large population and demands huge attention. Apart from gender, many other factors, such as obesity and diabetes, contribute to the rising incidence of UTIs.

Key Urinary Tract Infection (UTI) Treatment Market Trend

Rising R&D for effective treatment against superbugs/MDR microorganisms is a major trend influencing the urinary tract infection (UTI) treatment market growth. The development of MDR microorganisms is a huge challenge for the infectious disease industry, with hospital-acquired UTI being one of the major cases among them. Infections due to new species of microorganisms, which are also called superbugs, are resistant to most of the available treatments. These MDR microorganisms have a mortality rate of 25%-60%. This is a huge concern for healthcare providers across the globe. For instance, researchers at Queen's University Belfast, Ireland, have been studying the factors responsible for superbugs being resistant to the first line of treatment. This, in turn, has opened the opportunities to understand and develop a potential treatment to fight against killer infectious diseases. Countries all over the world are witnessing this problem, and therefore, a huge investment is expected in the development of their treatment. The EU, the Government of Canada, and a few developed countries have also taken various steps in developing innovative treatments against antimicrobial-resistant microorganisms.

Key Urinary Tract Infection (UTI) Treatment Market Challenge

The development of antibacterial resistance will be a major challenge for the urinary tract infection treatment market. UTI is primarily a bacterial infection. The development of antibacterial resistance organisms is a huge challenge for the global UTI treatment market. MDR microorganisms make UTIs more severe. MDR microorganisms are the species of organisms that exhibit resistance to several antimicrobial drugs. MDR bacteria are considered the most threatening group among all these organisms as they have shown a significant impact on public health. The MDR microorganisms, such as MDR E. coli, have been found to be a major infecting organism, especially in healthcare settings, and are a major point of concern for healthcare providers.

This urinary tract infection (UTI) treatment market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will h

Uncharacterized proteins have been underutilized as targets for the development of novel therapeutics for difficult-to-treat bacterial infections. To facilitate the exploration of these proteins, 2819 predicted, uncharacterized proteins (19.1% of the total) from reference strains of multidrug Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa species were organized using an unsupervised k-means machine learning algorithm. Classification using normalized values for protein length, pI, hydrophobicity, degree of conservation, structural disorder, and %AT of the coding gene rendered six natural clusters. Cluster proteins showed different trends regarding operon membership, expression, presence of unknown function domains, and interactomic relevance. Clusters 2, 4, and 5 were enriched with highly disordered proteins, nonworkable membrane proteins, and likely spurious proteins, respectively. Clusters 1, 3, and 6 showed closer distances to known antigens, antibiotic targets, and virulence factors. Up to 21.8% of proteins in these clusters were structurally covered by modeling, which allowed assessment of druggability and discontinuous B-cell epitopes. Five proteins (4 in Cluster 1) were potential druggable targets for antibiotherapy. Eighteen proteins (11 in Cluster 6) were strong B-cell and T-cell immunogen candidates for vaccine development. Conclusively, we provide a feature-based schema to fractionate the functional dark proteome of critical pathogens for fundamental and biomedical purposes.